Sagimet Biosciences SGMT 深 沪
已收盘 12-26 16:00:00 美东时间
5.96
-0.100
-1.65%
华盛通- 最 高6.05
- 今 开6.05
- 成交量 23.99万股
- 最 低 5.8679
- 昨 收 6.06
- 总市值 1.94亿
- 52周最高 11.41
- 市盈率 静 --
- 换手率 0.74%
- 52周最低 1.73
- 委 比 18.63%
- 总股本 3252.16万
- 历史最高 20.71
- 量 比 0.39
- 振 幅 3.00%
- 历史最低 1.73
- 每 手 1
- 风险率 2.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Sagimet Reports MASH Combo Data, Eyes Phase 2 for Liver Treatment
Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced positive results in the Phase 1
12-18 20:03
Sagimet Biosciences enters global license agreement with TAPI
Sagimet Biosciences, Inc. Class A ( ($SGMT) ) just unveiled an update. Sagimet ...
12-17 20:28
Sagimet Biosciences Announced A License Agreement With A Subsidiary Of Teva Pharmaceutical
License Agreement grants Sagimet a global, exclusive license to innovative forms of resmetirom active pharmaceutical ingredient (API) developed by TAPI and covered by TAPI patent applicationsCollaboration supports
12-17 20:06
Sagimet’s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China’s National Medical Products Administration
Sagimet Biosciences announced that China's NMPA has accepted the New Drug Application (NDA) for denifanstat, developed by Ascletis Pharma, to treat moderate to severe acne. Sagimet licensed denifanstat to Ascletis for China, while developing it for metabolic dysfunction-associated steatohepatitis (MASH) outside China. Denifanstat, as ASC40 in China, successfully met all endpoints in Phase 3 trials for acne. Sagimet is also exploring denifanstat i...
12-10 12:03
Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sagimet Biosciences Inc. has granted 42,800 stock options to three new employees under Nasdaq Rule 5635(c)(4). The options, with an exercise price based on the December 9, 2025, closing price, vest over four years and have a ten-year term. Sagimet, a clinical-stage biopharmaceutical company, focuses on developing FASN inhibitors targeting metabolic and fibrotic pathways. Its lead product, denifanstat, met Phase 2b and Phase 3 endpoints in metabol...
12-09 21:05
Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference
Sagimet Biosciences announced that its management will participate in the 8th Annual Evercore ISI Healthcare Conference on December 2, 2025, with a fireside chat at 12:55pm ET. A webcast of the event will be available on Sagimet’s website, with an archived replay for 90 days. Sagimet focuses on developing novel FASN inhibitors targeting metabolic and fibrotic pathways, with its lead product denifanstat showing positive results in clinical trials.
11-20 12:00
美股大行评级 | 花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级
花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级>>
11-17 10:49
Sagimet Biosciences shares are trading lower. The company reported Q3 financial results.
Sagimet Biosciences shares are trading lower. The company reported Q3 financial...
11-14 04:06
Sagimet Biosciences Q3 EPS $(0.40) Beats $(0.42) Estimate
Sagimet Biosciences (NASDAQ:SGMT) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.42) by 5.44 percent. This is a 11.11 percent increase over losses of $(0.45) per share
11-13 20:36
Sagimet Biosciences Presents Denifanstat Phase 2b Results Highlighting Advanced Fibrosis And Biomarker Improvements At AASLD 2025
A secondary analysis of FASCINATE-2 Phase 2 trial demonstrated denifanstat improved fibrosis, inflammation and steatosis in advanced qF4 MASH patients as measured by artificial intelligence (AI) digital pathologyIn a
11-10 20:19
